BioXcel Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2016
Net Income	-179.05	-165.76	-106.93	-82.17	-32.97	Upgrade
Depreciation & Amortization	0.32	0.33	0.3	0.19	0.16	Upgrade
Share-Based Compensation	18.61	17.34	19.46	14.61	3.14	Upgrade
Other Operating Activities	5.12	12.75	5.03	1.02	2.57	Upgrade
Operating Cash Flow	-155.01	-135.34	-82.15	-66.35	-27.1	Upgrade
Capital Expenditures	-0.02	-0.14	-0.45	-0.32	-0.87	Upgrade
Investing Cash Flow	-0.02	-0.14	-0.45	-0.32	-0.87	Upgrade
Share Issuance / Repurchase	26.73	0.28	102.45	247.36	17.81	Upgrade
Debt Issued / Paid	-0.18	95.95	0	0	0	Upgrade
Other Financing Activities	-0.03	-	-	-	0.02	Upgrade
Financing Cash Flow	26.52	96.24	102.45	247.36	17.83	Upgrade
Net Cash Flow	-128.5	-39.24	19.85	180.69	-10.14	Upgrade
Free Cash Flow	-155.03	-135.48	-82.6	-66.67	-27.97	Upgrade
Free Cash Flow Margin	-11233.77%	-36128.00%	-	-	-	Upgrade
Free Cash Flow Per Share	-5.32	-4.84	-3.13	-3.08	-1.72	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).